ClinicalTrials.gg
CompletedNCT01539031Updated Jun 18, 2023

Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease

A Phase 3 interventional study of E2020 and E2020 in Alzheimer's Type Dementia, sponsored by Eisai Co., Ltd.. Completed at 54 sites in Japan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by Eisai Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
351
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.

Enrollment
4th of 58
351 · median 79
Started
2012
with 1 other
Phase 3
10 of 60
1 open now
Registered
35th of 60
by date

Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 4th largest by enrollment of the 58 interventional ones that give a count, is one of 2 that started in 2012, is one of 10 in phase 3, and was the 35th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing donepezil in Alzheimer Disease, or all of them as a file.
02

Study summary

The purpose of this study is to compare 23 mg donepezil sustained release to the currently marketed formulation of 10 mg donepezil immediate release in patients with severe Alzheimer's disease.

03

Conditions studied

  • Alzheimer's Type Dementia

Keywords

  • Alzheimer Disease
  • Dementia
  • Delirium
  • Amnestic
  • Cognitive Disorders
  • Donepezil
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Tauopathies
  • Neurodegenerative Diseases
  • Mental Disorders
  • Cholinesterase Inhibitors
  • Enzy
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis: diagnostic evidence of probable Alzheimer's disease (AD) consistent with , Fourth Edition (DSM-IV-TR) 290.00 or 290.10
  • (MMSE) less than or equal to 12 and greater than or equal to1 inclusive, at Screening
  • SIB less than or equal to 90 and greater than or equal to10 at both Screening and Baseline
  • No evidence of focal disease to account for dementia on any cranial image (magnetic resonance imaging [MRI] or computed tomography [CT]).
  • Subject age range: male and female subjects greater than or equal to 50 years of age inclusive
  • Outpatients (patients in nursing homes are eligible)
  • The subject must have a caregiver who will provide separately for his/her own participation in the study, who will have regular contact with the subject.
  • Stable donepezil dose of 10 mg, taken as a single, daily dose for greater than or equal to 3 months prior to the Screening visit
  • Subjects who can swallow hole tablets, as tablets should not be broken or crushed
  • Comorbid medical conditions must be clinically stable prior to Screening unless otherwise specified.
  • Written informed consent will be obtained from the subject (if possible) or from the subject's legal guardian or other representative (according to Japanese regulations as appropriate) prior to beginning screening activities.

Exclusion criteria

Exclusion Criteria

  • Subjects with a known history of disorders that affect cognition or the ability to assess cognition but are distinguishable from AD
  • Subjects with dementia complicated by other organic disease or AD with delirium
  • Known to donepezil or piperidine derivatives, or to any of the in the study drug formulation
  • Patients who are expected to live in a nursing home within 24 weeks after randomization (eligible if temporary)
  • Use of any prohibited prior or concomitant medications. Memantine will be allowed if taken at prescribed doses that are less than or equal to 20 mg/day, provided that the dose has been stable for at least 6 months prior to Screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
351 participants (actual)

Study arms

  • Experimental
    10 mg group

    Drug: E2020

  • Active comparator
    23 mg group

    Drug: E2020

Interventions

  • DrugE2020

    Subjects in the Group-10 mg: Week 1 to 4: Once daily donepezil 10 mg and placebo matching donepezil 5 mg, Week 5 to 28: Once daily donepezil 10 mg and placebo matching donepezil 23 mg, Week 29 to 32: Once daily donepezil 5 mg, 10 mg and placebo matching donepezil 23 mg, Week 33 to 52: Once daily donepezil 23 mg

  • DrugE2020

    Subjects in the Group-23 mg: Week 1 to 4: Once daily donepezil 5 mg and 10 mg, Week 5 to 28: Once daily donepezil 23 mg and placebo matching donepezil 10 mg, Week 29 to 32: Once daily donepezil 23 mg, and placebo matching donepezil 5 mg and 10 mg, Week 33 to 52: Once daily donepezil 23 mg

06

What researchers measure

Primary outcomes

  1. The Severe Impairment Battery (SIB)

    SIB: change from Baseline to Week 24 in the total SIB score - Last Observation Carried Forward (LOCF)

    Time frame: 24 weeks

  2. The Clinician's Interview-Based Impression of Change, Plus Caregiver Input Version (CIBIC+)

    CIBIC+: overall change score at Week 24 - Last Observation Carried Forward (LOCF)

    Time frame: 24 weeks

07

Study locations

54 sites
  • Anjo, Aichi, Japan
  • Obu, Aichi, Japan
  • Toyoake, Aichi, Japan
  • Chikushi, Fukuoka, Japan
  • Kitakyushu, Fukuoka, Japan
  • Fukuoka, Gunma, Japan
  • Miyoshi, Hiroshima, Japan
  • Otake, Hiroshima, Japan
  • Amagasaki, Hyogo, Japan
  • Himeji, Hyogo, Japan
  • Morioka, Iwate, Japan
  • Kida, Kagawa, Japan
  • Takamatsu, Kagawa, Japan
  • Kawasaki, Kanagawa, Japan
  • Sagamihara, Kanagawa, Japan
  • Yokohama, Kanagawa, Japan
  • Yokosuka, Kanagawa, Japan
  • Maizuru, Kyoto, Japan
  • Nagasaki, Kyushu, Japan
  • Sendai, Miyagi, Japan
  • Kitamorokata, Miyazaki, Japan
  • Ina, Nagano, Japan
  • Nagaoka, Niigata, Japan
  • Kurashiki, Okayama, Japan
  • Ibaraki, Osaka, Japan
  • Ikeda, Osaka, Japan
  • Sakai, Osaka, Japan
  • Sennan, Osaka, Japan
  • Takatsuki, Osaka, Japan
  • Age, Saitama, Japan
  • Iruma, Saitama, Japan
  • Kasukabe, Saitama, Japan
  • Tokorozawa, Saitama, Japan
  • Fuji, Shizuoka, Japan
  • Izunokuni, Shizuoka, Japan
  • Anan, Tokushima, Japan
  • Bunkyo-ku, Tokyo, Japan
  • Kodaira, Tokyo, Japan
  • Koto, Tokyo, Japan
  • Ota-ku, Tokyo, Japan
  • Setagaya, Tokyo, Japan
  • Suginami, Tokyo, Japan
  • Akita, Japan
  • Chiba, Japan
  • Fukuoka, Japan
  • Hiroshima, Japan
  • Iwate, Japan
  • Kagoshima, Japan
  • Kochi, Japan
  • Kyoto, Japan
  • Nara, Japan
  • Osaka, Japan
  • Saitama, Japan
  • Tokushima, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Jan 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2012
First posted
Feb 27, 2012
Start
Mar 2012
Primary completionActual
Jan 2015
CompletionActual
Mar 2015
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01539031
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Feb 27, 2012
Start date
Mar 2012
Primary completion
Jan 2015
Completion
Mar 2015
Last update
Jun 18, 2023

Study contacts

Naoki Kubota
study director · Neuroscience Clinical Development Section, Japan/Asia Clinical Research Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion